BIOVOLF: Funding, Investors & Team (Sep 2026)

One of our goals is to address the worldwide shortage of food and protein for animals, which has become a significant challenge for producers. The rate of food production is no longer meeting the needs of a growing human population, and by 2050, protein production must double to keep up. Industries need to adopt new and improved methods of production to remain competitive. Our primary offering is a bioreactor technology that extracts entire plant proteins using sunlight and water. This process sequesters a remarkable amount of carbon dioxide from the atmosphere, and the resulting protein is superior to that found in chicken eggs. The technology can operate in any setting or climate, provides weekly harvests, predictable prices, and independence from supply chains. Multiple bioreactors can be linked to create an industrial cultivation chain without polluting the ecosystem, reducing the carbon footprint. This technology is ideal for farms, deserts, or even orbital stations. Currently, our clients are feed manufacturers and animal breeders. In the coming years, we intend to introduce five significant trials in Asia and Europe to provide fodder to corporations. Although we are based in Singapore, we have recently opened a branch in Dubai.

BIOVOLF has raised $200k across 1 round on record. The most recent is a Seed of $200k announced in Mar 2023.

BIOVOLF's most recent funding round on record is a Seed of $200k, announced in Mar 2023.

Ilya Paraushkin is listed as CEO at BIOVOLF.

BIOVOLF is based in Dubai, United Arab Emirates.

BIOVOLF is in the 1-10 employee band.

BIOVOLF's latest round of $200k is below the $3.3M median round size for Agriculture and Farming companies on FundedIQ across 1,320 tracked companies over the last two years.